(Q34297476)

1 August 2017

1 reference

title

Chemoprevention of breast cancer with fenretinide. (English)

1 reference

1 August 2017

Torrisi R

1

1 reference

1 August 2017

Decensi A

2

1 reference

1 August 2017

Formelli F

3

1 reference

1 August 2017

Camerini T

4

1 reference

1 August 2017

De Palo G

5

1 reference

1 August 2017

publication date

1 January 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

61

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

909-918

1 reference

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

1 August 2017

cites work

1 reference

12 December 2020

Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors

1 reference

12 December 2020

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

1 reference

12 December 2020

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors

1 reference

12 December 2020

Effects of fenretinide (4-HPR) on dark adaptation

1 reference

12 December 2020

Aberrant retinoid signaling and breast cancer: the view from outside the nucleus

1 reference

12 December 2020

Tolerability of the synthetic retinoid Fenretinide (HPR)

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells

1 reference

12 December 2020

Breast cancer prevention trials

1 reference

12 December 2020

Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

1 reference

12 December 2020

Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells

1 reference

12 December 2020

Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer

1 reference

12 December 2020

Unique anti-activator protein-1 activity of retinoic acid receptor beta

1 reference

12 December 2020

A new class of retinoids with selective inhibition of AP-1 inhibits proliferation

1 reference

12 December 2020

Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?

1 reference

12 December 2020

Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point

1 reference

12 December 2020

Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients

1 reference

12 December 2020

In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.

1 reference

12 December 2020

The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients

1 reference

12 December 2020

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

1 reference

12 December 2020

Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide

1 reference

12 December 2020

Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations

1 reference

12 December 2020

Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer.

1 reference

12 December 2020

Tamoxifen prevention of breast cancer: an instance of the fingerpost

1 reference

12 December 2020

Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit

1 reference

12 December 2020

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

1 reference

12 December 2020

N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat

1 reference

12 December 2020

Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients

1 reference

12 December 2020

Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene

1 reference

12 December 2020

Retinoids and apoptosis: implications for cancer chemoprevention and therapy

1 reference

12 December 2020

Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)

1 reference

12 December 2020

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

1 reference

12 December 2020

Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Chemoprevention of cancer

1 reference

12 December 2020

Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface

1 reference

12 December 2020

Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells

1 reference

12 December 2020

Chemoprevention of cancer with retinoids

1 reference

12 December 2020

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer

1 reference

12 December 2020

Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells

1 reference

12 December 2020

Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability

1 reference

12 December 2020

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

1 reference

12 December 2020

A decade of molecular biology of retinoic acid receptors

1 reference

12 December 2020

Can fenretinide protect women against ovarian cancer?

1 reference

12 December 2020

Cancer chemoprevention: progress and promise

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis

1 reference

12 December 2020

Distribution of fenretinide in the mammary gland of breast cancer patients

1 reference

12 December 2020

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

1 reference

12 December 2020

Tamoxifen and fenretinide in women with metastatic breast cancer

1 reference

12 December 2020

Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients

1 reference

12 December 2020

Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye

1 reference

12 December 2020

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

1 reference

12 December 2020

The taxanes: an update

1 reference

12 December 2020

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

1 reference

12 December 2020

Contralateral breast cancer: annual incidence and risk parameters.

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Clinical development plan: N-(4-hydroxyphenyl)retinamide

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/00003495-200161070-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1047405154

0 references

1 reference